The move comes a month after FDA issued a Complete Response Letter on the drug, despite pleas from patient advocates to approve a new treatment option in type 1 diabetes.
The European Commission yesterday approved sotagliflozin, a dual inhibitor sold as Zynquista, to be marketed in the European Union for certain overweight adults with type 1 diabetes (T1D). Sanofi is developing the drug with Lexicon Pharmaceuticals.
The move comes a month after the FDA issued a Complete Response Letter for sotagliflozin, which blocks both the sodium glucose cotransporter (SGLT) 1 and 2 proteins involved in the reabsorption of glucose otherwise expelled in the urine; SGLT1 reabsorbs glucose in the gastrointestinal tract, while SGLT2 reabsorbs it in the kidney. An FDA advisory panel split on recommending the drug for T1D based on a small but increased risk of diabetic ketoacidosis.
European Commission officials approved sotagliflozin, an oral therapy, for patients with a body mass index of 27 kg/m2 or more. It is available in once-daily doses of 200 mg or 400 mg.
“Zynquista’s dual mechanism of action provides important treatment benefits for adults with type 1 diabetes, including reducing blood sugar reabsorption in the kidneys through SGLT2 inhibition and delaying dietary sugar absorption through local SGLT1 inhibition in the intestinal tract,” said John Reed, MD, PhD, global head of research and development, Sanofi, in a statement.
Advocates in the T1D community have pressed FDA to approve sotagliflozin, after studies showed that it could reduce the glycemic variability they live with daily while treating their disease with insulin. Diabetes experts are increasingly emphasizing time in range as a more important measure than glycated hemoglobin, both as a measure of health in patients and a better predictor of long-term complications.
“Millions of people across Europe who live with type 1 diabetes struggle to control their blood sugar, even with optimal insulin therapy,” Thomas Danne, professor of pediatrics, Children’s Hospital ‘Auf der Bult,’ Hannover, Germany, said in a statement from Sanofi. “For the many people living with type 1 diabetes who are overweight or obese, Zynquista will offer a new treatment option that physicians can now consider in combination with insulin therapy for appropriate patients.”
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen